Free Trial
NASDAQ:GPCR

Structure Therapeutics Q3 2023 Earnings Report

Structure Therapeutics logo
$18.74 +0.01 (+0.05%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$18.86 +0.12 (+0.66%)
As of 05:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Structure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Structure Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Structure Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Structure Therapeutics Earnings Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
See More Structure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR), Inc. (NASDAQ: GPCR) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel small‐molecule modulators of G protein‐coupled receptors (GPCRs). Founded as a spin‐out from Sosei Heptares in early 2022, the company leverages a proprietary structure‐guided drug design platform to address high‐value therapeutic targets across pain, central nervous system, metabolic and immuno‐inflammatory disorders. Structure Therapeutics seeks to advance orally bioavailable, non‐opioid therapies by combining deep expertise in structural biology, medicinal chemistry and target validation.

The company’s research and development activities center on its proprietary GPCR platform, which integrates high‐resolution crystallography, computational modeling and advanced chemistry libraries. This platform allows Structure Therapeutics to systematically engineer receptor binding, selectivity and signaling profiles, accelerating the progression from target identification to clinical candidate. Its lead program, a selective modulator for chronic pain, is currently in early clinical evaluation and exemplifies the company’s approach to address unmet needs without relying on traditional opioid mechanisms.

Structure Therapeutics operates research facilities in Cambridge, UK, and Cambridge, Massachusetts, reflecting its commitment to maintaining strong discovery operations on both sides of the Atlantic. The company has established strategic partnerships and research collaborations with academic centers and biopharmaceutical organizations to expand its pipeline across multiple therapeutic areas. These alliances enhance its ability to rapidly advance preclinical candidates toward human studies while leveraging external expertise in disease biology and clinical development.

Under the leadership of CEO Robert Icke, a veteran in GPCR drug discovery, Structure Therapeutics is guided by a management team with extensive experience in bringing small‐molecule therapeutics from concept to market. The company’s board and scientific advisory committees feature industry leaders in structural biology, pharmacology and translational medicine. Together, they aim to harness the untapped potential of GPCR targets and deliver innovative therapeutics that improve patient outcomes worldwide.

View Structure Therapeutics Profile

More Earnings Resources from MarketBeat